Hansa Biopharma - Investorpræsentation
-
Presentation from Thursday around Gene Therapy by our Global Franchise Lead Lena Winstedt (in Swedish):
Hansa Biopharma har en betalt digital IR-aftale med Proinvestor.com
-
Opdateret analyse fra SEB.
112226_20230421_HNSA_SEB_Light_at_the_end_of_the_tunnel_just_came_in_view.pdf
-
Opdatering fra RedEye:
112227_20230421_HNSA_Redeye_Development_progress_combined_with_modest_sales.pdf
-
Opdatering fra ABG:
112228_20230421_HNSA_ABG_Improved_performance_later_in__23.pdf
-
Opdatering fra Erik Penser Bank:
112229_20230421_HNSA___EP_Hansa_Biopharma___Ljusning_i_horisonten.pdf
-
-
-
Shorting: Active positions for Hansa Biopharma
https://shortnordic.com/detaljer_selskap.php?company=hansa biopharma&land=sweden
-
Hansa Biopharma - Presentation of Q1 interim report 2023
Hansa Biopharma published its Q1 report on April 20th.
On that occasion, HC Andersen Capital will be hosting a digital event on Monday, April 24th at 13.00
https://www.inderes.dk/videos/inderes-presentation-of-q1-2023
-
The Chicago-based investment bank "William Blair" (analyst Matt Phipps) has initiated coverage on Hansa Biopharma
Hansa Biopharma AB (HNSA) - Turning the TIdeS: Imlifidase Provides a Novel Solution to Widen Transplant Access and Treat Antibody-Driven Acute Disease.
Læs hele analysen:
112289_20230424_HNSA___William_Blair_Turning_the_TIdeS__initiation_.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind